Patents Assigned to Quest Diagnostics
  • COMPOSITIONS AND METHODS FOR SCREENING SOLID TUMORS
    Publication number: 20200385817
    Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: May 8, 2020
    Publication date: December 10, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Kevin QU, James PRENTICE, Frederic WALDMAN
  • Detection of vitamins A and E by tandem mass spectrometry
    Patent number: 10859584
    Abstract: Methods are described for measuring the amount of one or more of vitamin A, ?-tocopherol, and the combination of ?-tocopherol and ?-tocopherol in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying one or more of vitamin A, ?-tocopherol, and the combination of ?-tocopherol and ?-tocopherol in a sample.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: December 8, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Sum Chan, Qibo Jiang
  • Determination of Antidepressants by Mass Spectrometry
    Publication number: 20200381228
    Abstract: Methods are described for detecting or determining the amount of antidepressants and/or antidepressant metabolites in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying antidepressants and/or antidepressant metabolites in a sample.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Anita Dermartirosian, Edith Shahbol, Karin Thomassian, Shaun Rezaei, Asad Shah
  • BCR-ABL VARIANTS
    Publication number: 20200378972
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Application
    Filed: August 10, 2020
    Publication date: December 3, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Maher ALBITAR
  • MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
    Patent number: 10851424
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: December 1, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • Mass spectrometry assay for estrogenic compounds during hormone replacement therapy
    Patent number: 10837971
    Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: November 17, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred Goldman, Nigel Clarke
  • Mass spectrometric determination of derivatized methylmalonic acid
    Patent number: 10837972
    Abstract: The invention relates to the detection of methylmalonic acid (MMA). In a particular aspect, the invention relates to methods for detecting derivatized methylmalonic acid (MMA) by mass spectrometry.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: November 17, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Scott M. Goldman, Julie A. Neidich, Denise Salazar, Thomas Lynn
  • DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20200354712
    Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.
    Type: Application
    Filed: May 29, 2020
    Publication date: November 12, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Heather R. Sanders
  • Quantitation of Tamoxifen and metabolites thereof by mass spectrometry
    Patent number: 10830746
    Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: November 10, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Nigel Clarke
  • DIRECT AMPLIFICATION AND DETECTION OF VIRAL AND BACTERIAL PATHOGENS
    Publication number: 20200340068
    Abstract: Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 29, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Maurice Exner, Luca Jacky, Yin-Peng Chen, Huong Mai, Michelle M. Tabb, Michael Aye
  • Methods and compositions for detecting BK virus
    Patent number: 10801078
    Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 13, 2020
    Assignee: Quest Diagnostics Infectious Disease, Inc.
    Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
  • AUTOMATED ANALYSIS OF ANALYTICAL GELS AND BLOTS
    Publication number: 20200319140
    Abstract: The present solution describes an automated system for analyzing analytical gels or blots, such as electrophoresis gels. The system can automatically detect the lanes within the gel and convert the lane into a feature vector that can be compared to reference datasets. Based on a comparison of the feature vector to the reference datasets, the system can automatically classify the feature vector (and the test sample in the lane) into a phenotype group.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Nilesh Saratkar, Stanley Naides, Michelle A. Cleveland
  • Methods for detecting norovirus
    Patent number: 10793924
    Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: October 6, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
  • Cystic fibrosis gene mutations
    Patent number: 10793910
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 6, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Matthew J. McGinniss, Arlene M Buller, Franklin Quan, Mei Peng, Weimin Sun
  • C peptide detection by mass spectrometry
    Patent number: 10782305
    Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: September 22, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel Clarke, Zhaohui Chen
  • MPL mutations in JAK2 V617F negative patients with myeloproliferative disease
    Patent number: 10782299
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 22, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • QUANTITATION OF INSULIN BY MASS SPECTROMETRY
    Publication number: 20200284808
    Abstract: Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Application
    Filed: October 7, 2019
    Publication date: September 10, 2020
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Zhaohui CHEN, Nigel CLARKE
  • CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS
    Publication number: 20200270687
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: August 27, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • Mass spectrometric determination of non-derivatized, non-metabolized vitamin D
    Patent number: 10753950
    Abstract: The invention relates to the detection of non-metabolized vitamin D. In a particular aspect, the invention relates to methods for detecting underivatized non-metabolized vitamin D by mass spectrometry.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: August 25, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Brett Holmquist, Nigel Clarke
  • Vial for sampling assembly
    Patent number: D902429
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: November 17, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Nikita Ganeshan